Discover 138 paid clinical trials in Shreveport, Louisiana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 138
Active & Responsive
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)
for
Plantar Fibromatosis, Ledderhose Disease
Location: 53 recruiting locations
Sponsor: Endo Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06151197
Phase3, Recruiting
Active & ResponsiveNew
Dual System Study: Transvaginal Fetal Pulse Oximetry Measurement Systems
for
Fetal Hypoxia, Fetal Acidemia
Location: 1 recruiting location
Sponsor: Raydiant Oximetry, Inc.
Sex: Female
Age: 18+
Code: NCT07296419
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
for
Moderately to Severely Active Ulcerative Colitis
Location: 49 recruiting locations
Sponsor: Hoffmann-La Roche
Sex: All
Age: 16 - 70+
Code: NCT06588855
Phase3, Recruiting
Active & Responsive
STRIVE Post-Market Registry Study
for
Emphysema
Location: 11 recruiting locations
Sponsor: Olympus Corporation of the Americas
Sex: All
Age: 18+
Code: NCT04302272
Recruiting
Active & Responsive
ACP-204 in Adults With Alzheimer's Disease Psychosis
for
Alzheimer's Disease Psychosis
Location: 23 recruiting locations
Sponsor: ACADIA Pharmaceuticals Inc.
Sex: All
Age: 55 - 70+
Code: NCT06159673
Phase2, Phase3, Recruiting
Active & Responsive
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition
for
Kidney Disease
Location: 17 recruiting locations
Sponsor: Takeda
Sex: All
Age: 18+
Code: NCT06963827
Phase3, Recruiting
Active & Responsive
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention